Skip to main content
Search form
Search
Subscribe to newsletter +
European Association of Hospital Pharmacists
Menu
Main menu
Home
About Us
Who we are
Board
Staff
Students
Transparency
Contact Information
Call for Expressions of Interest
Members
Associate membership
News
Press Releases
EAHP Newsletters
EAHP in the news
Multimedia Gallery
Events
Calendar
Academy
Synergy Masterclass
EAHP BOOST
Congresses
General Assemblies
Accreditations
EAHP Synergy Certification Courses
Open Learning
Get Involved
Sponsors and partners
HP Practice
EAHP COVID-19 Resource Centre
European Statements of Hospital Pharmacy
What hospital pharmacists do
EAHP-ESCP Oath to Society
FIP global statements
National legislation on hospital pharmacy
Good Practice Initiatives
Common training framework
Environmental Sustainability
European Council for Pharmacy Education Accreditation
Investigation of the hospital pharmacy profession in Europe
Hospital Pharmacy Day
SIGs
Controlled Substances Management
Special Interest Group on Investigation of medication errors and efficiency in oncology
Automated Medication Management
Working Towards Eliminating Avoidable Harm
Hazardous Medicinal Products
Hospital Pharmacist’s Preparedness for in-vivo gene therapy medicinal products
Investigation of Medication Errors in Intensive Care Units
Use of Prefilled Syringes in Intensive Care Units and Operating Theaters
Policy
Resources
Consultations
Position Papers
Get involved and keep up to date
Access to Medicines
Ageing society
Infectious Diseases and AMR
ATMPs
Bar coding medicines to the single unit
Biosimilar medicines
Clinical trials
Digital Health
EMA - EAHP collaboration
European List of Emergency Medicines
Falsified Medicines
Hazardous Medicinal Products
Hospital Pharmacy Specialisation
Medical device regulation
Medicines shortages
Patient safety
Pharmaceuticals in the environment
Pharmacy preparations and compounding
Procurement
Public spending austerity
SmPC
Vaccination
Workforce
Statements
GPIs
Publications
2019 EP Election Manifesto
General information
EAHP Annual report
European Journals of Hospital Pharmacy
EAHP Surveys of HP practice
EAHP History Book
Practical Pharmaceutics
Congress presentation webcasts
2024 European Parliament Election Manifesto
Member Center
You are here
Home
Section 5: Patient Safety and Quality Assurance
5PSQ-077
COST-EFFECTIVENESS OF BIOSIMILAR ETANERCEPT IN CLINICAL PRACTICE USE
5PSQ-076
SWITCHING BIOLOGIC TREATMENTS: EXPERIENCE OF A REGIONAL HOSPITAL
5PSQ-075
INTRODUCTION OF BIOSIMILAR ETANERCEPT: AN ITALIAN DISTRICT ANALYSIS
5PSQ-074
CANAKINUMAB IN FAMILIAL MEDITERRANEAN FEVER AND SECONDARY AMYLOIDOSIS: A CASE REPORT
5PSQ-073
MUCORMYCOSIS INDUCED BY INAPPROPIATE USE OF ORAL CORTICOIDS – A CASE REPORT
5PSQ-072
ACUTE PROMYELOCYTIC LEUKAEMIA AFTER INFLIXIMAB THERAPY IN A CROHN'S DISEASE PATIENT: A CASE REPORT AND A REVIEW OF THE LITERATURE
5PSQ-071
EVALUATION OF THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
5PSQ-070
INFLUENCE OF PATHOLOGY IN INJECTION PAIN REDUCTION WITH A NEW FORMULATION OF ORIGINAL ADALIMUMAB
5PSQ-069
ABSTRACT WITHDRAWN
5PSQ-068
ADHERENCE TO DISEASE-MODIFYING THERAPIES IN SPANISH PATIENTS WITH MULTIPLE SCLEROSIS
5PSQ-067
DETECTION OF ADVERSE NEUROPSYCHIATRIC REACTIONS ASSOCIATED WITH ABIRATERONE AND ENZALUTAMIDE TREATMENTS IN THE HOSPITAL
5PSQ-066
THE OTHER SIDE OF IMMUNOTHERAPY: SAFETY AND TOXICITY MANAGEMENT IN CLINICAL PRACTICE
5PSQ-065
MANIC SYMPTOMATOLOGY INDUCED BY ALECTINIB: A CASE REPORT
5PSQ-064
INTENSIVE MONITORING OF AFATINIB – CASE REPORT
5PSQ-063
MORE RISK OF NEUTROPAENIA IN OBESE PATIENTS TREATED WITH PACLITAXEL?
Pages
« first
‹ previous
…
45
46
47
48
49
50
51
52
53
…
next ›
last »
Follow Us